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Background: Cervical cancer ranks second among all cancers reported in Sri Lankan women. This study assessed
the prevalence and type-distribution of human papillomavirus (HPV) among Sri Lankan women with invasive
cervical cancer (ICC) and pre-cancerous lesions.
Methods: 114 women aged 21 years and above, hospitalized in the National Cancer Institute, Sri Lanka with a
diagnosis of ICC or cervical intraepithelial neoplasia (CIN) 2/3 were prospectively enrolled between October 2009
and September 2010 (110430/NCT01221987). The cervical biopsy or excision specimens collected during routine
clinical procedures were subjected to histopathological review. DNA was extracted from samples with a confirmed
histological diagnosis and was amplified using polymerase chain reaction and HPV DNA was detected using
Enzyme Immuno Assay. HPV positive samples were typed using reverse hybridization Line Probe Assay.
Results: Of the cervical samples collected, 93.0% (106/114) had a histologically confirmed diagnosis of either ICC
(98/106) or CIN 2/3 (8/106). Among all ICC cases, squamous cell carcinoma was diagnosed in the majority of
women (81.6% [80/98]). HPV prevalence among ICC cases was 84.7% (83/98). The HPV types most commonly
detected in ICC cases with single HPV infection (98.8% [82/83]) were HPV-16 (67.3%) and HPV-18 (9.2%). Infection
with multiple HPV types was recorded in a single case (co-infection of HPV-16 and HPV-59).
Conclusions: HPV was prevalent in most women with ICC in Sri Lanka; HPV-16 and HPV-18 were the predominantly
detected HPV types. An effective prophylactic vaccine against the most prevalent HPV types may help to reduce
the burden of ICC disease.
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Worldwide disease burden data indicate that invasive
cervical cancer (ICC) is the third most common type of
cancer and the fourth most common cause of death due
to cancer in women [1], with an estimated 530,000 new
cases and nearly 275,000 deaths occurring each year [1].
According to the World Health Organization (WHO)
estimates, ICC ranks as the second most common can-
cer among women causing approximately 1,395 new
cases and nearly 814 deaths annually in Sri Lanka [2].* Correspondence: johannes.e.schmidt@gsk.com
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article, unless otherwise stated.It is a well-established fact that persistent infection
with oncogenic (or high-risk) human papillomavirus
(HPV) is an important contributor for the development
of ICC [3-5]. HPV can be detected in the vast majority
of ICC specimens and corresponds to the highest attrib-
utable fraction as a causative agent for any major human
cancer worldwide [4]. The overall prevalence of HPV in
women with ICC has been reported to be as high as
99.7% around the world [4] and nearly 90% in Asia [5].
HPV-16 and HPV-18 are the most frequently reported
HPV types, causing approximately 70% of ICC cases
worldwide [1,3,6].
Cytological screening of the cervix using the Pap smear
test and the early detection of HPV play an important rolentral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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HPV-associated mortality [3]. However, due to a lack of
effective screening programs in lower and middle-income
countries, including Sri Lanka, detection of cervical ab-
normalities is often difficult and leads to higher mortality
rates, due to ICC, in these settings [7]. Nevertheless, re-
cent molecular biological techniques such as HPV-DNA
testing, have been found to be effective HPV screening
methods and may facilitate early detection of ICC in de-
veloping regions [8].
Prophylactic vaccination represents a potential primary
prevention measure against ICC [1,3]. Two prophylactic
vaccines containing virus-like particles that offer protec-
tion against cervical pre-cancers and cancers are available:
a bivalent vaccine (Cervarix™ [GlaxoSmithKline, Belgium])
containing virus-like particles for HPV-16 and −18 and a
quadrivalent vaccine (Gardasil™ [Merck and Co., Inc,
Whitehouse Station, New Jersey, USA]) containing virus-
like particles for HPV-6, -11, -16 and −18 [7]. A recent
systematic review and meta-analysis indicated that these
vaccines are safe, well tolerated and efficacious against the
vaccine-HPV types that caused persistent infection and
cervical disease in young women [9]. Although both these
vaccines have been licensed in Sri Lanka and are available
in the private sector since 2009, they have not been in-
cluded in the national immunization program [2].
Recent data on the prevalence of HPV infection and
its type-distribution are limited in Sri Lanka and there-
fore this study was undertaken with the primary object-
ive of assessing the prevalence of HPV-16, HPV-18 and
other oncogenic HPV types among Sri Lankan women
with a diagnosis of ICC and cervical intraepithelial neo-
plasia 2/3 (CIN 2/3). Such data is critical for assessing
the potential impact of prophylactic HPV vaccines in Sri
Lanka.
Methods
Study design and population
This cross-sectional, descriptive, observational study was
conducted between October 2009 and September 2010
(110430/NCT01221987). Women aged 21 years and above
who were hospitalized in the National Cancer Institute,
Sri Lanka, with a confirmed histological diagnosis of ICC,
squamous cell carcinoma (SCC), adenosquamous carcin-
oma (ASC), glandular lesions (including adenocarcinoma
[ADC] and adenocarcinoma in-situ [AIS]), and CIN 2/3
(including carcinoma in situ) were prospectively enrolled.
Women were excluded from the study if they had received
previous vaccination against HPV, prior chemotherapy or
radiotherapy for ICC, or if they had a history of recurrent
episodes of ICC or CIN 2/3.
At the time of enrollment, the prevalence of HPV-16
and −18 were assumed to be 50% and 16%, respectively
in ICC cases and 30% and 7%, respectively in CIN2/3cases [10]. Assuming 10% of non-evaluable cases, an en-
rollment of 200 women (100 ICC and 100 CIN 2/3
cases) was planned.
This study was approved by a national Independent
Ethics Committee in Sri Lanka and all the study proce-
dures were conducted according to the principles of
Good Clinical Practice, the Declaration of Helsinki ver-
sion 1996 and local regulations. Written informed con-
sent was collected from all women prior to the study
conduct.
Laboratory procedures
Cervical biopsy or excision specimens obtained during
routine clinical diagnostic/operational procedures were
fixed in 10% formalin solution and embedded in paraffin
as tissue blocks. The review of excision specimen and
verification of initial histopathological diagnosis was per-
formed by the site pathologist and classified as ICC or
CIN 2/3.
Sectioning of tissue blocks was undertaken by sand-
wich technique, whereby tissue sections for polymerase
chain reaction (PCR) were flanked by tissue sections for
histopathological review at DDL Diagnostic Laboratory,
the Netherlands. A review and final diagnosis was per-
formed by the pathologist at DDL Diagnostic Laboratory
to confirm the diagnosis made by the site pathologist. If
there was a disagreement between the two diagnoses, a
third opinion was sought from a pathologist at DDL
Diagnostic Laboratory. The final diagnosis was made by
simple majority and the samples were confirmed to be
ICC or CIN 2/3.
Following histopathological review and the confirm-
ation of ICC or CIN2/3, DNA extraction was performed
using proteinase K digestion [11]. Amplification of the
extracted DNA was undertaken using PCR-SPF10 (ver-
sion 1) method and HPV DNA was detected using DNA
Enzyme Immuno Assay. HPV-positive specimens were
typed using reverse hybridization Line Probe Assay
(LiPA) using the 25 type-specific hybridization probes
[11,12]. This method aided in the detection of 14 onco-
genic HPV types (HPV-16, -18, -31, -33, -35, -39, -45, -51,
-52, -56, -58, -59, -66 and −68) and 11 non-oncogenic
HPV types (HPV-6, -11, -34, -40, -42, -43, -44, -53, -54,
-70 and −74). All laboratory assays were performed at
DDL Diagnostic Laboratory, the Netherlands.
Statistical analyses
The histologically confirmed cohort included all women
with confirmed diagnoses of ICC or CIN 2/3.
The percentage of women with ICC and CIN2/3 and
positive for HPV-16, HPV-18 or other oncogenic HPV
types was tabulated with 95% confidence interval (CI).
The proportion of women positive for either HPV-16 or
HPV-18 and having a co-infection with other oncogenic
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and HPV-18 by histological diagnosis were also tabu-
lated. All analyses were performed using statistical ana-
lysis system (SAS) version 9.2.Results
A total of 114 women were enrolled in this study, of
whom 106 (93.0%) were included in the histologically
confirmed cohort. A definite pathological diagnosis of
ICC or CIN 2/3 was not confirmed in eight women due
to insufficient ICC/CIN samples left in cervical biopsy
specimen collected, thus the original cervical specimen
was missing when the tissue blocks were prepared. The
mean age of all enrolled women was 52.6 years (standard
deviation 9.62 years); all women were of Sri Lankan
origin.Histological diagnosis
In the histologically confirmed cohort, 92.5% (98/106) of
women were diagnosed with ICC and 7.5% (8/106) were
diagnosed with CIN 2/3. In women with ICC, SCC and
ADC accounted for 81.6% (80/98) and 12.2% (12/98) of
cases, respectively; six women were diagnosed with cer-
vical cancer of other histological types. The histologicalTable 1 Histological diagnoses and HPV status of women (His
Histological diagnosis HPV status








ADC n’ = 12
HPV +
Single infection
ASC n’ = 1 HPV -
UDC n’ = 1
HPV +
Single infection
ON n’ = 1
HPV +
Single infection
MIC n’ = 2
HPV +
Single infection
AIS n’ = 1
HPV +
Single infection
CIN 2/3 n’ = 8
HPV +
Single infection
N: Total number of women in the histologically confirmed cohort. n: Number of wo
Prevalence of HPV infection. HPV-: HPV infection not present. 95% CI: 95% confiden
squamous cell carcinoma; ADC, adenocarcinoma; ASC, adenosquamous carcinoma;
cinoma in situ; MIC, microinvasive carcinoma; CIN, cervical intraepithelial neoplasia.diagnoses and the HPV infection status of women in the
histologically confirmed cohort are detailed in Table 1.
HPV prevalence and type distribution
The overall prevalence of HPV infection in women with
ICC was 84.7% ([95% CI: 76.0–91.2]; 83/98), of which
98.8% ([95% CI: 93.5–100.0]; 82/83) were infected with a
single HPV type and 1.2% ([95% CI: 0.0–6.5]; 1/83) had
multiple HPV type infection (Table 1).
Among women with SCC and ADC, HPV prevalence
was 90.0% ([95% CI: 81.2–95.6]; 72/80) and 50.0% ([95%
CI: 21.1–78.9]; 6/12), respectively (Table 1).
The HPV type distribution among women with ICC,
by histological diagnosis, is illustrated in Figure 1. HPV-
16 was detected in 67.3% women ([95% CI: 57.1–76.5];
66/98) and HPV-18 in 9.2% ([95% CI: 4.3–16.7]; 9/98).
Other oncogenic HPV types included HPV-45, HPV-59
and HPV-68 each was detected in two women (2.0%
[95% CI: 0.2–7.2]), and HPV-52, HPV-56 and HPV-70
each detected in one women (1.0% [95% CI: 0.0–5.6])
(Figure 1). Co-infection of HPV-16 and HPV-59 was ob-
served in a single case (1.5% [95% CI: 0.0–8.2]) of ICC.
All eight CIN 2/3 cases were HPV positive (100.0% [95%
CI: 63.1–100.0]), with HPV-16 being the most predom-
inant type detected (50.0% [95% CI: 15.7–84.3]) followedtologically confirmed cohort [N = 106])




















men in each category. n’: Number of women by histological diagnosis. HPV+:
ce intervals. LL: Lower limit. UL: Upper limit. ICC, invasive cervical cancer; SCC,
UDC, undifferentiated carcinoma; ON, other invasive neoplasm; AIS, adenocar-
Figure 1 HPV prevalence and type distribution among adult women with cervical lesions (Histologically confirmed cohort [N = 106]).
Note: The error bars indicate the 95% confidence intervals. HPV-45, -59 and −68 accounted for 2% women each and HPV-52, -56 and −70
accounted for 1% women each.
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56 (12.5% [95% CI: 0.3–52.7], respectively) (Figure 1).
Non-oncogenic HPV types were not detected in any
woman in the histologically confirmed cohort.
Discussion
This descriptive observational study provides the most
recent data on the prevalence and type distribution of
HPV in Sri Lankan women aged 21 years or more with
a diagnosis of ICC. The overall prevalence of HPV in
women with histologically confirmed ICC in our study
(84.7%) was lower than the 93% rate previously re-
ported by Samarawickrema et al. [13] in a retrospective
study using archival cervical tissue samples to assess
HPV type distribution in a similar Sri Lankan population.
Samarawickrema et al. employed reverse hybridization
technique using INNO-LiPA HPV Genotyping Extra Kit
(Innogenetics, Gent, Belgium) for HPV DNA detection
and typing [13], which is a modified version of the original
SPF10- DEIA/LiPA25 PCR system (SPF10-LiPA25 version 1
[licensed Innogenetics technology, manufactured by Labo
Biomedical Products, Rijswijk, The Netherlands]) [14]
which we used. In addition to using similar laboratory
procedures, Samarawickerma et al. performed HPV typing
on all ICC cases [13], which is similar to the present study.
However, Samarawickerma study [13] used archival cer-
vical biopsy specimens to assess the prevalence and type-
distribution of HPV which is in contrast to the design of
the present study. Although this could partly explain the
difference in overall HPV prevalence rates between the
two studies, the exact reason is uncertain.In the present study, the HPV prevalence in women
with SCC was 90.0%, which is in line with a meta-analysis
of published literature in Asian women with SCC where
the adjusted overall HPV prevalence was 86.1% [5].
HPV-16 (67.3%) and HPV-18 (9.2%) were the most
prevalent HPV types in ICC cases. This corresponds to
worldwide estimates of approximately 70% of ICC cases
which are caused by these HPV types [1,3]. The preva-
lence of HPV-16 reported in this study was lower when
compared to other studies in Sri Lankan women with in-
vasive SCC (74%–77%) [13,15], but higher than that re-
ported from a worldwide surveillance study by Sanjose
et al. (61%) [16]. On the other hand, the prevalence of
HPV-18 in this study was lower when compared to that
reported by de Silva et al. (20%) [15] and Sanjose et al.
(10%) [16] but higher than that reported in a study by
Samarawickrema et al. (6.5%) [13]. This highlights the
need for a vaccine which offers broader protection, irre-
spective of type, as non-HPV-16/-18 lesions may play a
substantial role in the local disease burden [17].
Although a meta-analysis of global studies found that
infection with multiple HPV types is common [18], in
the current study, only one woman with ICC was in-
fected with multiple HPV types. A similar observation
was made in a previously conducted study in Sri Lanka
where only one case with multiple HPV type infection
was reported amongst 108 women diagnosed with inva-
sive SCC [13]. However, the exact reason for the ob-
served fewer multiple infections are unknown.
The strengths of this study include the confirmation of
histopathological diagnosis of ICC and/or CIN 2/3 cases
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highly sensitive SPF10-LiPA assay for detecting HPV
DNA, which provides scientific validity and ensures
comparability of the results with studies conducted
worldwide using similar methodologies. Since the cer-
vical specimens were prospectively collected, they were
more recent and might have resulted in higher HPV
DNA detection rates as compared to studies which use
archival specimens [13,16].
However, the results have to be interpreted with cau-
tion due to several limitations. Firstly, the present study
evaluated only HPV positive ICC cases and did not in-
vestigate the extent to which HPV negative cases might
in fact be false negatives. Among ICC cases in this study,
15.3% (15/98) tested negative for HPV DNA. Failure to
detect HPV DNA in ICC cases, despite persistent HPV
infection being postulated to be a “necessary cause” of
ICC, may be due to inadequate sampling or disruption
of the PCR target sequence due to viral integration [4].
Such an observation was made by Walboomers and
colleagues when they re-assessed HPV negative ICC
specimens from the International Biological Study on
Cervical Cancer study [19] and concluded that at least
40 of the 66 HPV-negative ICC specimens tested using
MY09/11 PCR assay were indeed false negatives [4]. Sec-
ondly, the number of CIN 2/3 cases enrolled was lower
than planned (100 CIN 2/3 cases) because the recruiting
centers were tertiary hospitals which mainly treated in-
vasive cancers. In Sri Lanka, structured and organized
cervical screening programs are lacking and cervical
smears are only collected opportunistically [20]. As a
consequence, only the most severe ICC cases are likely
to be detected. Furthermore, the ineffective screening
programs could result in the relatively lower detection
rates of pre-cancerous cases which in turn might have
led to small number of CIN 2/3 cases enrolled in this
study. Therefore, because of selection bias, the selected
sample size is non-representative of the population and
further studies with sufficient cases will be required to
better understand the prevalence and type distribution
of HPV infection among precancerous lesions. Lastly, al-
though the prevalence and distribution of HPV types
might vary among histological diagnosis of ICC (SCC
and ADC), the primary objective of the study was to as-
sess the prevalence and distribution of HPV types
among all ICC cases only. In addition, the number of
ADC cases in the study was low (n = 12) thus no conclu-
sion on HPV prevalence in ADC could be drawn.
WHO recommends that HPV vaccination be included
in the national immunization programs of countries
where ICC and/or other HPV-related diseases constitute
a public health priority [2]. Recently conducted clinical
trials of the bivalent and quadrivalent vaccines indicated
that both vaccines had high efficacy against CIN inwomen who were not previously infected with HPV
[21,22]. Indeed, in Sri Lanka, the nationwide introduc-
tion of effective prophylactic vaccines, which provide
protection against the prevalent HPV types, might help
to effectively reduce the long-term HPV-associated dis-
ease burden of ICC. Sri Lanka has a considerably lower
maternal mortality ratio compared to other countries in
South Asia (1 in 430 as compared to 1 in 43, respect-
ively) [23], which is the direct result of improved educa-
tion and cost-free health care, advances in knowledge
and infrastructure of healthcare facilities, improvements
in nutrition, sanitation and immunization practices [24].
The implementation of a comprehensive strategy, com-
bining HPV vaccination together with effective cervical
screening programs might substantially help to enhance
women’s health in Sri Lanka.Conclusions
HPV infection was prevalent in the majority of Sri Lankan
women with ICC. HPV-16 and HPV-18 were the predom-
inant HPV types in this population. An effective prophy-
lactic vaccine, which offers protection against oncogenic
HPV types, may therefore help to reduce the disease bur-
den of ICC in a comprehensive cervical cancer prevention
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